GlassScriptPhysician profile
William A Okerblom
NPI 1396893046
$1,395.12
in general payments reported to CMS, 2019-2025
25 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $45.39 · 2021: $182 · 2022: $160 · 2023: $192 · 2024: $361 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $132.16 | 2019-2024 | Rybelsus, Ozempic |
| Viiv Healthcare Company | $103.00 | 2023 | Apretude |
| Novartis Pharmaceuticals Corporation | $98.57 | 2019-2024 | |
| Lilly USA, LLC | $98.17 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $98.16 | 2021-2025 | Airsupra |
| Pfizer INC. | $93.69 | 2024-2025 | |
| Leo Pharma INC. | $87.88 | 2024-2025 | Anzupgo, Adbry |
| Bayer Healthcare Pharmaceuticals INC. | $84.64 | 2022-2025 | |
| Amarin Pharma, INC. | $82.54 | 2019-2021 | |
| Amgen INC. | $62.30 | 2020-2025 | Repatha, Otezla, Evenity |
| Incyte Corporation | $59.73 | 2024 | Opzelura |
| Glaxosmithkline, LLC. | $58.70 | 2019-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.30 | 2024 | Spevigo |
| Janssen Pharmaceuticals, INC | $39.45 | 2019 | |
| Abbvie INC. | $35.99 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.36 | 2022-2024 | Xifaxan |
| Exact Sciences Corporation | $24.76 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $23.88 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.31 | 2025 | Ultomiris |
| Tempus Ai, INC | $21.72 | 2025 | Xt Cdx |
| Allergan, INC. | $20.90 | 2019 | |
| Genzyme Corporation | $19.77 | 2023 | |
| Esperion Therapeutics, INC. | $19.20 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Okerblom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.